CLASS ACTION UPDATE for BLUE, CLOV and LDOS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders – Yahoo Finance

0
51

NEW YORK, NY / ACCESSWIRE / March 8, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BLUE Shareholders Click Here: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=13447&wire=1
CLOV Shareholders Click Here: https://www.zlk.com/pslra-1/clover-health-investments-corp-loss-submission-form?prid=13447&wire=1
LDOS Shareholders Click Here: https://www.zlk.com/pslra-1/leidos-holdings-inc-loss-submission-form?prid=13447&wire=1

* ADDITIONAL INFORMATION BELOW *

bluebird bio, Inc. (NASDAQ:BLUE)

BLUE Lawsuit on behalf of: investors who purchased May 11, 2020 – November 4, 2020
Lead Plaintiff Deadline: April 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=13447&wire=1

According to the filed complaint, during the class period, bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird’s BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Clover Health Investments, Corp. (NASDAQ:CLOV)

CLOV Lawsuit on behalf of: investors who purchased October 6, 2020 – February 3, 2021
Lead Plaintiff Deadline: April 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/clover-health-investments-corp-loss-submission-form?prid=13447&wire=1

According to the filed complaint, during the class period, Clover Health Investments, Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) Clover was the recipient of a Civil Investigative Demand from the DOJ; (ii) much of Clover’s sales are driven by a major related party deal that Clover not only failed to disclose but took active steps to conceal; (iii) Clover’s
subsidiary Seek Insurance failed to disclose its relationship with Clover and misled consumers as to its purported independence; (iv) Clover’s software was in fact rudimentary; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Leidos Holdings, Inc. (NYSE:LDOS)

LDOS Lawsuit on behalf of: investors who purchased May 4, 2020 – February 23, 2021
Lead Plaintiff Deadline: May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/leidos-holdings-inc-loss-submission-form?prid=13447&wire=1

According to the filed complaint, during the class period, Leidos Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the purported benefits of the Company’s acquisition of L3Harris’ Security Detection & Automation businesses were significantly overstated; (2) Leidos’ products suffered from numerous product defects, including faulty explosive detection systems at airports, ports, and borders; (3) as a result of the foregoing, the Company’s financial results were significantly overstated; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:
https://www.accesswire.com/634198/CLASS-ACTION-UPDATE-for-BLUE-CLOV-and-LDOS-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

LEAVE A REPLY

Please enter your comment!
Please enter your name here